Microbiome Analytical Methods Patents: Who Leads, Where Gaps Are 2026
Microbiome analytical methods patents: absolute quantification, DNA extraction bias and strain-level resolution
44.6% concentration. The five leading assignees hold 100 of 224 records in scope, but the tenth-ranked entrant still has 8 — a long tail sits underneath a top cluster, not a monopoly. Filings rose from 13 in 2017 to a peak of 28 in 2021, then eased to 24 by 2024 — a 14% pullback over that three-year span. The 2025-2026 figures are undercounted because publication has not caught up with filing yet.
- 1UNIVERSITY OF LAUSANNE33
- 2THE BROAD INST INC23
- 3THE GENERAL HOSPITAL CORP18
- 4MASSACHUSETTS INST OF TECH16
- 5UNIV HEALTH NETWORK10
See the full microbiome analytical methods analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this landscape
Who holds the most patents in microbiome analytical methods?
Ownership in this 224-record dataset is led by a single academic research institute holding 33 records, well ahead of the fifth-ranked assignee at 10. The top five assignees combined hold 100 records, or 44.6% of all records in scope, while the top ten hold 143, or 63.8%. Beneath that top cluster sits a long tail of single- and low-filing entrants, so the field is concentrated at the top without being a monopoly.
Is patent filing in microbiome analytical methods growing or slowing?
Filings rose steadily from 13 in 2017 to a peak of 28 in 2021, then eased to 24 by 2024 — a 14% pullback over that three-year span, based on complete-year data. Figures for 2025 and 2026 are still incomplete because patent publication typically lags filing by around 18 months, so it is too early to call this a slowdown. The more accurate read is a plateau around established methods rather than declining interest.
What technology areas dominate microbiome analytical methods patents?
Enzyme and DNA measurement methods, classified under C12Q, appear in 54.5% of the 224 records in scope, making it the single densest area of claim activity. Material analysis and testing methods (G01N) follow at 36.6%. Bioinformatics (G16B) and healthcare informatics (G16H) are present but much thinner, at 16.5% and 9.4% respectively, indicating the computational and software side of microbiome analysis carries comparatively less claim density than the wet-lab measurement side.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Microbiome Analytical Methods covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.